Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The FierceBiomarkers e-newsletter has compiled a brief report with the above title that may be of interest to some of our readers.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, prognosis, test | Leave a Comment »
Many readers will already have seen the report we posted about Senator McCain’s desire to eliminate the Prostate Cancer Research Program within the Congressionally Directed Medical Research Program (CDMRP) — one of the most successful prostate cancer research initiatives. Now you can work with the rest of the advocacy community to counter this.
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: advocacy, CDMRP, eliminate, McCain, Prostate Cancer Research Program | 3 Comments »
A new analysis of data from the multi-center @-Registry of patients undergoing Ablatherm-based high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer suggests that nadir levels of PSA post-treatment can be used to predict the probability of biochemical progression-free survival (bPFS) at 5 years of follow-up.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, nafir, outcome, prognosis, PSA | Leave a Comment »
There is good reason to believe that a very high percentage of older men — particularly those over 75 years with low-risk prostate cancer who have a life expectancy of 10 years or less — will get little to no clinical or survival benefit from active therapeutic intervention (although they should clearly be carefully monitored [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk, Treatment | Tagged: active, comorbidity, elderly. life expectancy, surveillance, Treatment | 2 Comments »
Out of the 600+ presentations at the IMPaCT meeting in Orlando last week, your correspondent somehow managed to overlook an interesting poster that offers new evidence in support of the potential benefit of statin therapy in the prevention and management of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Prevention, progression, statin, trial | 2 Comments »
A report from the Centers for Disease Control, issued last week, suggests that as of January 1, 2007 there were nearly 2.3 million men living in the U.S. after a diagnosis of prostate cancer.
Filed under: Living with Prostate Cancer | Tagged: prevalence, USA | 2 Comments »
Craig Turner, MD, practices urology in Portland, Oregon, and for the past 6 years or so he has been carrying out laparoscopic radical prostatectomies with the help of a da Vinci robot … but he doesn’t seem to think this has made him a better prostate cancer surgeon.
Filed under: Management, Treatment | Tagged: care, economics, outcome, quality, RALP, technology | 1 Comment »
It has long been understood that a finding of “atypia” (atypical small acinar proliferation) on an initial biopsy of the prostate is associated with an increased risk for prostate cancer, and a repeat biopsy is normally recommended for any patient with an initial finding of atypia.
Filed under: Diagnosis, Management, Risk | Tagged: acinar proliferation, ASAP, atypia, biopsy, follow-up | 3 Comments »
We have known for a while that men with a tertiary Gleason grade of 4 or 5 (as discussed below) are at heightened risk for progressive forms of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: Gleason, grade, pattern, prognosis, risk, tertiary | 1 Comment »
The PCPT prostate cancer risk calculator is a widely used tool designed to help men and their doctors assess whether they should have a prostate biopsy based on the patient’s age, PSA level, and supplementary data. The calculator asks about family history of prostate cancer in one simple question requiring only a Yes/No answer.
Filed under: Diagnosis, Risk | Tagged: calculator, family history, risk, specificity | Leave a Comment »
According to a media release on the BusinessWire web site earlier this week, Adamis Pharmaceuticals has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration seeking the ability to initiate a 30-patient Phase I/IIa clinical trial
Filed under: Uncategorized | Leave a Comment »
So the question any smart prostate cancer patient should ask himself — especially if he has any degree of good scientific education — is, “How do I get myself invited to the next IMPaCT meeting?”
Filed under: Living with Prostate Cancer | Tagged: CDMRP, consumer reviewer, IMPACT, participate, Prostate Cancer Research Program | Leave a Comment »
One of the other major initiatives that have been funded over several years by the Department of Defense’s Prostate Cancer Research Program is the North Carolina-Louisiana Prostate Cancer Project (often just known as PCaP).
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, disparities, ethnicity, race, risk | Leave a Comment »
Most medical-scientific meetings that deal (at least in part) with prostate cancer are inhabited by academic scientists, clinicians, and various types of representative of commercial companies.
Filed under: Living with Prostate Cancer, Management | Tagged: CDMRP, Department of Defense, IMPACT, Prostate Cancer Research Program | 2 Comments »
Senator John McCain is a man who has been treated successfully not once, not twice, but three times for malignant melanoma.
Filed under: Uncategorized | Tagged: CDMRP, funding, McCain, PCRP, research | 7 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site